J2A-MC-GZGP A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502839-19-00

Acronym

J2A-MC-GZGP

Enrollment

516

Registered

2023-09-04

Start date

2023-09-14

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight, Overweight or Obesity

Brief summary

Mean Percent Change from Baseline in Body Weight [Time Frame: Baseline to Week 72]

Interventions

DRUGSodium Bicarbonate - Placebo to match LY3502970

DRUGORFORGLIPRON

DRUGOrforglipron

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean Percent Change from Baseline in Body Weight [Time Frame: Baseline to Week 72]	—

Countries

Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026